ÂÜÀòÂÒÂ×

Bernie Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.

Previously, Mr. Tobin held several senior-level positions at Amgen including General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence. In addition, he led the global integration of a business development acquisition in over 100 countries. Prior to that, Mr. Tobin held a variety of leadership roles in the commercial organization at Eli Lilly and Co. He received his B.S. degree in Public Service and Administration from Iowa State University and his M.B.A. from the Fuqua School of Business, Duke University.